Cl[C:2]1[N:7]=[C:6]([CH:8]([F:10])[CH3:9])[CH:5]=[CH:4][N:3]=1.C1(P(C2C=CC=CC=2)C2C3OC4C(=CC=CC=4P(C4C=CC=CC=4)C4C=CC=CC=4)C(C)(C)C=3C=CC=2)C=CC=CC=1.C(=O)([O-])[O-].[Cs+].[Cs+].[CH3:59][C:60]1[CH:61]=[C:62]([CH:64]=[C:65]([C:67]2[CH:68]=[N:69][N:70]([CH2:72][C:73]([CH3:75])=[CH2:74])[CH:71]=2)[CH:66]=1)[NH2:63]>O1CCOCC1.C([O-])(=O)C.[Pd+2].C([O-])(=O)C>[F:10][CH:8]([C:6]1[CH:5]=[CH:4][N:3]=[C:2]([NH:63][C:62]2[CH:64]=[C:65]([C:67]3[CH:68]=[N:69][N:70]([CH2:72][C:73]([CH3:75])=[CH2:74])[CH:71]=3)[CH:66]=[C:60]([CH3:59])[CH:61]=2)[N:7]=1)[CH3:9]2-Chloro-4-(1-fluoroethyl)pyrimidine (170 mg, 1.06 mmol), Palladium(II) acetate (59.3 mg, 0.26 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (229 mg, 0.40 mmol), and cesium carbonate (860 mg, 2.64 mmol) were added to a solution of 3-methyl-5-(1-(2-methylallyl)-1H-pyrazol-4-yl)aniline (300 mg, 1.32 mmol) in dioxane (2.5 mL). The solution was degassed by sparging with Ar for 5 minutes and stirred at 110° C. for 18 h. The mixture was allowed to cool to room temperature, diluted with EtOAc, and washed with brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (10-30% EtOAc/Hexane), then further purified by reverse phase HPLC (ACN/water with 0.1% TFA modifier) to afford 4-(1-fluoroethyl)-N-(3-methyl-5-(1-(2-methylallyl)-1H-pyrazol-4-yl)phenyl)pyrimidin-2-amine MS ESI calc'd. for C20H23FN5 [M+H]+ 352. found 352.
Wird geladen…